| 1 | Guide to Understanding and Supporting International Medical Graduates in Hematology/Oncology by the ASCO International Medical Graduates Community of Practice | 2.9 | 4 | Citations (PDF) |
| 2 | Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial | 9.9 | 52 | Citations (PDF) |
| 3 | A neoantigen vaccine generates antitumour immunity in renal cell carcinoma | 37.9 | 167 | Citations (PDF) |
| 4 | CDK4/6 Inhibition With Abemaciclib in Patients With Previously Treated Advanced Renal Cell Carcinoma | 2.3 | 2 | Citations (PDF) |
| 5 | Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma | 25.1 | 33 | Citations (PDF) |
| 6 | Stereotactic Body Radiation Therapy Alone or in Combination with Immunotherapy in Kidney Cancer: A Systematic Review | 2.1 | 10 | Citations (PDF) |
| 7 | Tumor-Intrinsic and Microenvironmental Determinants of Impaired Antitumor Immunity in Chromophobe Renal Cell Carcinoma | 16.9 | 11 | Citations (PDF) |
| 8 | KIM-1 as a Prognostic Marker in Renal Cell Carcinoma | 3.5 | 11 | Citations (PDF) |
| 9 | TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type | 3.4 | 20 | Citations (PDF) |
| 10 | Changes in Prostate-specific Antigen Screening after the 2018 United States Preventive Services Task Force Recommendations and Through the COVID-19 Pandemic | 5.8 | 13 | Citations (PDF) |
| 11 | Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma | 3.4 | 21 | Citations (PDF) |
| 12 | The 5th Kidney Cancer Research Summit: Research Accelerating Cures for Renal Cell Carcinoma in 2023 | 3.4 | 7 | Citations (PDF) |
| 13 | A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma | 3.4 | 3 | Citations (PDF) |
| 14 | PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti–PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients | 6.8 | 39 | Citations (PDF) |
| 15 | Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study | 16.9 | 159 | Citations (PDF) |
| 16 | The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214 | 3.4 | 5 | Citations (PDF) |
| 17 | Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma | 25.1 | 11 | Citations (PDF) |
| 18 | Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes 2024, 12, e008724 | | 8 | Citations (PDF) |
| 19 | Reply to Yudai Ishiyama and Fumihiko Urabe’s Letter to the Editor re: Kosuke Takemura, Audreylie Lemelin, Matthew S. Ernst, et al. Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.01.006 | 2.1 | 1 | Citations (PDF) |
| 20 | Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens | 3.4 | 4 | Citations (PDF) |
| 21 | Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions | 25.2 | 50 | Citations (PDF) |
| 22 | Detecting Small Cell Transformation in Patients with Advanced
EGFR
Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling | 6.8 | 32 | Citations (PDF) |
| 23 | Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma | 10.6 | 27 | Citations (PDF) |
| 24 | Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214 2024, 12, e009495 | | 14 | Citations (PDF) |
| 25 | Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial | 9.9 | 195 | Citations (PDF) |
| 26 | Liquid biopsy in renal cell carcinoma | 3.4 | 9 | Citations (PDF) |
| 27 | Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas | 3.4 | 30 | Citations (PDF) |
| 28 | Epigenomic charting and functional annotation of risk loci in renal cell carcinoma | 13.7 | 36 | Citations (PDF) |
| 29 | Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study | 27.4 | 152 | Citations (PDF) |
| 30 | Patients’ Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19 | 3.4 | 10 | Citations (PDF) |
| 31 | Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer | 3.4 | 7 | Citations (PDF) |
| 32 | Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma | 4.2 | 17 | Citations (PDF) |
| 33 | Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer | 22.5 | 28 | Citations (PDF) |
| 34 | Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma | 2.2 | 8 | Citations (PDF) |
| 35 | Oligometastatic Bladder Cancer: Defining a Novel Entity | 2.1 | 4 | Citations (PDF) |
| 36 | Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases 2023, 11, e007240 | | 18 | Citations (PDF) |
| 37 | Liquid biopsy epigenomic profiling for cancer subtyping | 33.0 | 111 | Citations (PDF) |
| 38 | Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors | 4.6 | 52 | Citations (PDF) |
| 39 | Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101 | 5.3 | 9 | Citations (PDF) |
| 40 | LITESPARK-012: Pembrolizumab Plus Lenvatinib With or Without Belzutifan or Quavonlimab for Advanced Renal Cell Carcinoma | 2.3 | 27 | Citations (PDF) |
| 41 | First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial | 2.1 | 74 | Citations (PDF) |
| 42 | Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study | 1.8 | 1 | Citations (PDF) |
| 43 | The impact of COVID-19 on cancer care and oncology clinical research: an experts’ perspective | 5.3 | 37 | Citations (PDF) |
| 44 | Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial | 6.8 | 32 | Citations (PDF) |
| 45 | FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma | 1.6 | 15 | Citations (PDF) |
| 46 | HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study | 27.4 | 113 | Citations (PDF) |
| 47 | Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States | 6.6 | 10 | Citations (PDF) |
| 48 | First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape | 3.4 | 28 | Citations (PDF) |
| 49 | Integrative clinical and molecular characterization of translocation renal cell carcinoma | 6.3 | 111 | Citations (PDF) |
| 50 | Towards a Better Understanding of Antibody-Drug Conjugates in Urothelial Carcinoma | 5.8 | 2 | Citations (PDF) |
| 51 | Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial | 27.4 | 81 | Citations (PDF) |
| 52 | Anti-CAIX BBζ CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model | 4.9 | 28 | Citations (PDF) |
| 53 | Computed Tomography Texture Analysis for Predicting Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors | 3.4 | 5 | Citations (PDF) |
| 54 | Soluble PD-L1 as an early marker of progressive disease on nivolumab 2022, 10, e003527 | | 62 | Citations (PDF) |
| 55 | Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis | 6.8 | 64 | Citations (PDF) |
| 56 | Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study | 0.8 | 16 | Citations (PDF) |
| 57 | Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma 2022, 10, e004316 | | 104 | Citations (PDF) |
| 58 | Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer | 6.6 | 64 | Citations (PDF) |
| 59 | Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma | 4.0 | 233 | Citations (PDF) |
| 60 | Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial | 6.8 | 20 | Citations (PDF) |
| 61 | Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials | 6.8 | 48 | Citations (PDF) |
| 62 | Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study | 27.4 | 54 | Citations (PDF) |
| 63 | Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors | 2.3 | 24 | Citations (PDF) |
| 64 | COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE) | 5.3 | 25 | Citations (PDF) |
| 65 | Recent Advances in Tivozanib plus Nivolumab Combinatorial Strategies in Renal Cell Carcinoma | 0.0 | 0 | Citations (PDF) |
| 66 | Impact of MET status on treatment outcomes in papillary renal cell carcinoma: A pooled analysis of historical data | 4.9 | 14 | Citations (PDF) |
| 67 | Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma | 6.6 | 17 | Citations (PDF) |
| 68 | Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma | 2.1 | 1 | Citations (PDF) |
| 69 | Obesity in Relation to Renal Cell Carcinoma Incidence and Survival in Three Prospective Studies | 2.1 | 31 | Citations (PDF) |
| 70 | Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021) | 27.4 | 67 | Citations (PDF) |
| 71 | Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial | 27.4 | 293 | Citations (PDF) |
| 72 | An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma | 251.5 | 30 | Citations (PDF) |
| 73 | Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy | 4.9 | 32 | Citations (PDF) |
| 74 | The (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage | 25.1 | 16 | Citations (PDF) |
| 75 | Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma | 6.8 | 22 | Citations (PDF) |
| 76 | Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy | 3.4 | 19 | Citations (PDF) |
| 77 | Triethylene Glycol Can Be Predeployed as a Safe Virus-Killing Indoor Air Treatment | 3.7 | 6 | Citations (PDF) |
| 78 | Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial | 4.9 | 16 | Citations (PDF) |
| 79 | A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer | 10.6 | 27 | Citations (PDF) |
| 80 | Germline variants associated with toxicity to immune checkpoint blockade | 33.0 | 101 | Citations (PDF) |
| 81 | IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma | 33.0 | 67 | Citations (PDF) |
| 82 | Summary From the First Kidney Cancer Research Summit, September 12–13, 2019: A Focus on Translational Research | 4.6 | 25 | Citations (PDF) |
| 83 | Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma | 6.8 | 76 | Citations (PDF) |
| 84 | Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies | 4.0 | 92 | Citations (PDF) |
| 85 | Health care spending in prostate cancer: An assessment of characteristics and health care utilization of high resource-patients | 1.8 | 4 | Citations (PDF) |
| 86 | A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma | 3.4 | 43 | Citations (PDF) |
| 87 | Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma | 6.8 | 226 | Citations (PDF) |
| 88 | Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors | 5.8 | 33 | Citations (PDF) |
| 89 | Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells | 6.8 | 37 | Citations (PDF) |
| 90 | ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma | 12.5 | 49 | Citations (PDF) |
| 91 | A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy | 2.5 | 42 | Citations (PDF) |
| 92 | Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival | 6.6 | 277 | Citations (PDF) |
| 93 | Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma | 13.7 | 160 | Citations (PDF) |
| 94 | Next Steps: Sequencing Therapies in Metastatic Kidney Cancer in the Contemporary Era | 4.4 | 12 | Citations (PDF) |
| 95 | Trans-ethnic variation in germline variants of patients with renal cell carcinoma | 6.3 | 23 | Citations (PDF) |
| 96 | Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial | 2.1 | 63 | Citations (PDF) |
| 97 | Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma | 34.5 | 1,624 | Citations (PDF) |
| 98 | Post-acute COVID-19 syndrome | 33.0 | 4,356 | Citations (PDF) |
| 99 | Temporal Trends and Predictors in the Use of Stereotactic Body Radiotherapy for Treatment of Metastatic Renal Cell Carcinoma in the U.S | 3.4 | 10 | Citations (PDF) |
| 100 | Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic | 14.3 | 241 | Citations (PDF) |
| 101 | Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial | 4.9 | 24 | Citations (PDF) |
| 102 | Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC 2021, 9, e001506 | | 37 | Citations (PDF) |
| 103 | Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma | 34.5 | 1,610 | Citations (PDF) |
| 104 | Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials | 2.3 | 47 | Citations (PDF) |
| 105 | Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR) | 3.4 | 10 | Citations (PDF) |
| 106 | Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis | 33.0 | 280 | Citations (PDF) |
| 107 | OncoAlert Round Table Discussions: The Global COVID-19 Experience | 2.1 | 6 | Citations (PDF) |
| 108 | Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma | 33.0 | 558 | Citations (PDF) |
| 109 | Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature | 5.8 | 74 | Citations (PDF) |
| 110 | Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial | 2.1 | 44 | Citations (PDF) |
| 111 | Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma | 14.3 | 32 | Citations (PDF) |
| 112 | Progressive immune dysfunction with advancing disease stage in renal cell carcinoma | 33.0 | 438 | Citations (PDF) |
| 113 | Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial | 5.3 | 42 | Citations (PDF) |
| 114 | Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium | 9.9 | 295 | Citations (PDF) |
| 115 | Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma | 6.8 | 22 | Citations (PDF) |
| 116 | CDKN2A Alterations and Response to Immunotherapy in Solid Tumors | 6.8 | 107 | Citations (PDF) |
| 117 | Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) – an International mRCC Database Consortium (IMDC) analysis | 1.8 | 23 | Citations (PDF) |
| 118 | Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumors | 4.3 | 21 | Citations (PDF) |
| 119 | B2B: Kidney Cancer Summary | 0.3 | 0 | Citations (PDF) |
| 120 | Care without a compass: Including patients with cancer in COVID-19 studies | 33.0 | 15 | Citations (PDF) |
| 121 | Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials | 4.9 | 47 | Citations (PDF) |
| 122 | Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19 | 14.3 | 183 | Citations (PDF) |
| 123 | Metabolic reprogramming in renal cancer: Events of a metabolic disease | 7.0 | 161 | Citations (PDF) |
| 124 | Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma | 34.5 | 686 | Citations (PDF) |
| 125 | Recovery of cancer screening tests and possible associated disparities after the first peak of the COVID-19 pandemic | 33.0 | 38 | Citations (PDF) |
| 126 | Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma | 2.9 | 17 | Citations (PDF) |
| 127 | RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting | 1.6 | 4 | Citations (PDF) |
| 128 | RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse | 1.6 | 57 | Citations (PDF) |
| 129 | Neurotoxicities of novel non-steroidal anti-androgens for prostate cancer: A systematic review and meta-analysis | 5.0 | 6 | Citations (PDF) |
| 130 | Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study | 2.6 | 15 | Citations (PDF) |
| 131 | Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma | 2.3 | 19 | Citations (PDF) |
| 132 | Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors | 4.9 | 15 | Citations (PDF) |
| 133 | Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE) | 0.6 | 3 | Citations (PDF) |
| 134 | Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium | 2.6 | 39 | Citations (PDF) |
| 135 | Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma | 70.7 | 304 | Citations (PDF) |
| 136 | Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma | 14.3 | 65 | Citations (PDF) |
| 137 | Pathogenicity of VHL variants in families with non-syndromic von Hippel-Lindau phenotypes: An integrated evaluation of germline and somatic genomic results | 1.6 | 14 | Citations (PDF) |
| 138 | Comparison of Equations To Estimate Glomerular Filtration Rate and Their Impact on Frequency of Cisplatin-associated Acute Kidney Injury | 1.8 | 7 | Citations (PDF) |
| 139 | Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial | 6.8 | 53 | Citations (PDF) |
| 140 | Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19 | 6.6 | 37 | Citations (PDF) |
| 141 | Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset | 13.7 | 47 | Citations (PDF) |
| 142 | CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer | 5.5 | 33 | Citations (PDF) |
| 143 | State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era | 3.5 | 7 | Citations (PDF) |
| 144 | Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma | 5.8 | 85 | Citations (PDF) |
| 145 | Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma | 1.9 | 12 | Citations (PDF) |
| 146 | Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma | 0.5 | 3 | Citations (PDF) |
| 147 | Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma | 4.9 | 26 | Citations (PDF) |
| 148 | The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy | 5.8 | 29 | Citations (PDF) |
| 149 | Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma | 2.3 | 3 | Citations (PDF) |
| 150 | Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma | 4.2 | 64 | Citations (PDF) |
| 151 | Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer | 14.3 | 12 | Citations (PDF) |
| 152 | Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer | 25.1 | 318 | Citations (PDF) |
| 153 | Novel Therapeutic Approaches and the Evolution of Drug Development in Advanced Kidney Cancer | 1.8 | 24 | Citations (PDF) |
| 154 | Quality‐adjusted survival with first‐line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance) | 4.0 | 15 | Citations (PDF) |
| 155 | Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer | 1.8 | 4 | Citations (PDF) |
| 156 | Prostate cancer reactivates developmental epigenomic programs during metastatic progression | 25.2 | 266 | Citations (PDF) |
| 157 | Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial 2020, 8, e000891 | | 195 | Citations (PDF) |
| 158 | Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial | 4.0 | 301 | Citations (PDF) |
| 159 | Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial | 5.3 | 481 | Citations (PDF) |
| 160 | Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma 2020, 8, e001467 | | 34 | Citations (PDF) |
| 161 | Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study | 33.0 | 66 | Citations (PDF) |
| 162 | Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study | 25.1 | 124 | Citations (PDF) |
| 163 | Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial | 33.0 | 449 | Citations (PDF) |
| 164 | Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma | 6.8 | 19 | Citations (PDF) |
| 165 | LBA71 Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis | 9.9 | 20 | Citations (PDF) |
| 166 | The Impact of Age and Gender on Outcomes of Patients With Advanced Renal Cell Carcinoma Treated With Targeted Therapy | 2.3 | 14 | Citations (PDF) |
| 167 | Geographic Distribution of Racial Differences in Prostate Cancer Mortality | 6.6 | 64 | Citations (PDF) |
| 168 | Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma | 9.9 | 429 | Citations (PDF) |
| 169 | Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study 2020, 8, e000538 | | 31 | Citations (PDF) |
| 170 | Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study | 62.1 | 1,569 | Citations (PDF) |
| 171 | Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma | 2.5 | 35 | Citations (PDF) |
| 172 | Efficacy of Savolitinib vs Sunitinib in Patients WithMET-Driven Papillary Renal Cell Carcinoma | 14.3 | 155 | Citations (PDF) |
| 173 | Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma | 33.0 | 857 | Citations (PDF) |
| 174 | Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes | 33.0 | 262 | Citations (PDF) |
| 175 | Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma | 4.9 | 63 | Citations (PDF) |
| 176 | Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101 | 3.9 | 42 | Citations (PDF) |
| 177 | Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome—Results from the International Metastatic Renal Cell Carcinoma Database Consortium | 5.8 | 53 | Citations (PDF) |
| 178 | The role of site-specific therapy for cancers of unknown of primary: A meta-analysis | 4.9 | 35 | Citations (PDF) |
| 179 | Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma | 4.2 | 65 | Citations (PDF) |
| 180 | Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma | 2.1 | 58 | Citations (PDF) |
| 181 | Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors | 4.2 | 74 | Citations (PDF) |
| 182 | Current Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma | 4.4 | 45 | Citations (PDF) |
| 183 | Patient‐reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma | 3.2 | 28 | Citations (PDF) |
| 184 | Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma 2020, 8, e000144 | | 77 | Citations (PDF) |
| 185 | COVID-19 and Cancer: Current Challenges and Perspectives | 33.0 | 255 | Citations (PDF) |
| 186 | Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors | 4.2 | 63 | Citations (PDF) |
| 187 | Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial | 27.4 | 724 | Citations (PDF) |
| 188 | The Future of Perioperative Therapy in Advanced Renal Cell Carcinoma: How Can We Prosper? | 2.3 | 39 | Citations (PDF) |
| 189 | Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial | 3.4 | 26 | Citations (PDF) |
| 190 | Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer | 2.3 | 13 | Citations (PDF) |
| 191 | Myocarditis in the Setting of Cancer Therapeutics | 18.0 | 416 | Citations (PDF) |
| 192 | Sex specific associations in genome wide association analysis of renal cell carcinoma | 3.0 | 37 | Citations (PDF) |
| 193 | Safety and efficacy of CDX-014, an antibody-drug conjugate against T Cell immunoglobulin mucin-1 (TIM-1), in advanced renal cell carcinoma | 9.9 | 0 | Citations (PDF) |
| 194 | Pathologic scoring of pre-treatment H&E biopsies predicts overall survival in patients with metastatic clear cell renal cell carcinoma receiving nivolumab monotherapy | 9.9 | 1 | Citations (PDF) |
| 195 | Response of Primary Renal Cell Carcinoma to Systemic Therapy | 2.1 | 11 | Citations (PDF) |
| 196 | Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma 2019, 7, | | 26 | Citations (PDF) |
| 197 | PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN | 6.8 | 56 | Citations (PDF) |
| 198 | First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium | 2.1 | 83 | Citations (PDF) |
| 199 | Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma | 14.3 | 219 | Citations (PDF) |
| 200 | Metabolomic adaptations and correlates of survival to immune checkpoint blockade | 13.7 | 201 | Citations (PDF) |
| 201 | The Effect of Weight Change During Treatment With Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma | 2.3 | 4 | Citations (PDF) |
| 202 | irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial | 6.8 | 99 | Citations (PDF) |
| 203 | Lenvatinib Plus Everolimus or Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Study Design and Rationale | 2.3 | 47 | Citations (PDF) |
| 204 | A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer | 6.8 | 35 | Citations (PDF) |
| 205 | Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial | 62.1 | 957 | Citations (PDF) |
| 206 | Real-World Outcomes of Nivolumab and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium | 3.0 | 29 | Citations (PDF) |
| 207 | Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up | 9.9 | 449 | Citations (PDF) |
| 208 | Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer? | 4.0 | 8 | Citations (PDF) |
| 209 | A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis | 13.7 | 803 | Citations (PDF) |
| 210 | Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | 34.5 | 2,326 | Citations (PDF) |
| 211 | Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study | 27.4 | 160 | Citations (PDF) |
| 212 | COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma | 2.3 | 16 | Citations (PDF) |
| 213 | An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma | 3.4 | 27 | Citations (PDF) |
| 214 | Utility of FDG-PET/CT in Patients with Advanced Renal Cell Carcinoma with Osseous Metastases: Comparison with CT and
99m
Tc-MDP Bone Scan in a Prospective Clinical Trial | 0.5 | 2 | Citations (PDF) |
| 215 | Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium | 5.8 | 37 | Citations (PDF) |
| 216 | Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies | 2.3 | 13 | Citations (PDF) |
| 217 | Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites | 6.8 | 135 | Citations (PDF) |
| 218 | The influence of obesity-related factors in the etiology of renal cell carcinoma—A mendelian randomization study | 8.0 | 74 | Citations (PDF) |
| 219 | Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer | 2.1 | 52 | Citations (PDF) |
| 220 | Activation of c-Met in cancer cells mediates growth-promoting signals against oxidative stress through Nrf2-HO-1 | 5.6 | 63 | Citations (PDF) |
| 221 | Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race‐based differences in survival? | 4.0 | 28 | Citations (PDF) |
| 222 | Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9–10 Prostate Cancer | 2.1 | 28 | Citations (PDF) |
| 223 | Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions | 2.1 | 212 | Citations (PDF) |
| 224 | The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort | 3.5 | 53 | Citations (PDF) |
| 225 | Contemporary national trends in prostate cancer risk profile at diagnosis | 4.0 | 59 | Citations (PDF) |
| 226 | A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma | 5.5 | 77 | Citations (PDF) |
| 227 | Risk of dementia following androgen deprivation therapy for treatment of prostate cancer | 4.0 | 21 | Citations (PDF) |
| 228 | Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals | 4.2 | 42 | Citations (PDF) |
| 229 | Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign | 4.2 | 5 | Citations (PDF) |
| 230 | Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial | 27.4 | 261 | Citations (PDF) |
| 231 | Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade Prostate Cancer | 2.1 | 100 | Citations (PDF) |
| 232 | Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma | 5.5 | 36 | Citations (PDF) |
| 233 | Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer | 4.2 | 43 | Citations (PDF) |
| 234 | The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma | 6.3 | 708 | Citations (PDF) |
| 235 | The Immune Landscape of Cancer | 22.6 | 5,116 | Citations (PDF) |
| 236 | Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients | 4.4 | 38 | Citations (PDF) |
| 237 | Hypothyroidism During Tyrosine Kinase Inhibitor Therapy Is Associated with Longer Survival in Patients with Advanced Nonthyroidal Cancers | 4.4 | 34 | Citations (PDF) |
| 238 | The effect of treatment at minority-serving hospitals on outcomes for bladder cancer | 1.8 | 27 | Citations (PDF) |
| 239 | Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis | 4.2 | 79 | Citations (PDF) |
| 240 | Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial | 27.4 | 351 | Citations (PDF) |
| 241 | Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events | 4.2 | 61 | Citations (PDF) |
| 242 | Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study | 6.8 | 55 | Citations (PDF) |
| 243 | The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases | 2.3 | 14 | Citations (PDF) |
| 244 | Comparative effectiveness of robot-assisted vs. open radical cystectomy | 1.8 | 65 | Citations (PDF) |
| 245 | Evaluation of disease‐free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial‐level meta‐analysis | 4.0 | 41 | Citations (PDF) |
| 246 | Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer | 9.9 | 33 | Citations (PDF) |
| 247 | Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy | 2.3 | 15 | Citations (PDF) |
| 248 | Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update | 4.9 | 355 | Citations (PDF) |
| 249 | Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma | 34.5 | 4,298 | Citations (PDF) |
| 250 | Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce | 2.0 | 13 | Citations (PDF) |
| 251 | Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer | 2.1 | 21 | Citations (PDF) |
| 252 | Characterization of Patients With Poor-Risk Metastatic Renal-Cell Carcinoma: Results From a Pooled Clinical Trials Database | 2.3 | 1 | Citations (PDF) |
| 253 | Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer | 2.3 | 19 | Citations (PDF) |
| 254 | Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis | 2.1 | 66 | Citations (PDF) |
| 255 | Variation in the use of active surveillance for low‐risk prostate cancer | 4.0 | 43 | Citations (PDF) |
| 256 | Rheumatologic symptoms in oncologic patients on PD-1 inhibitors | 3.8 | 55 | Citations (PDF) |
| 257 | Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics | 2.1 | 53 | Citations (PDF) |
| 258 | Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA | 2.1 | 74 | Citations (PDF) |
| 259 | Non–Clear Cell Renal Cell Carcinomas: From Shadow to Light | 16.9 | 55 | Citations (PDF) |
| 260 | Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma | 16.9 | 85 | Citations (PDF) |
| 261 | Impact of Aspirin and Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs on Outcomes in Patients with Metastatic Renal Cell Carcinoma | 0.5 | 4 | Citations (PDF) |
| 262 | Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151 | 9.9 | 4 | Citations (PDF) |
| 263 | Sequential Response to FGFR3 Inhibition With Subsequent Exceptional Response to Atezolizumab in a Patient With FGFR3-TACC3 Fusion–Positive Metastatic Urothelial Carcinoma | 1.9 | 1 | Citations (PDF) |
| 264 | Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study | 27.4 | 132 | Citations (PDF) |
| 265 | Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders 2018, 6, | | 81 | Citations (PDF) |
| 266 | Investigating the effect of treatment at high-volume hospitals on overall survival following cytoreductive nephrectomy | 1.8 | 2 | Citations (PDF) |
| 267 | Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma | 3.2 | 17 | Citations (PDF) |
| 268 | Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium | 4.0 | 62 | Citations (PDF) |
| 269 | Use of Preventive Health Services Among Cancer Survivors in the U.S. | 3.2 | 13 | Citations (PDF) |
| 270 | Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma | 5.5 | 34 | Citations (PDF) |
| 271 | Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma | 5.5 | 82 | Citations (PDF) |
| 272 | Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2) | 5.5 | 48 | Citations (PDF) |
| 273 | Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis | 2.1 | 89 | Citations (PDF) |
| 274 | Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor–Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases | 6.8 | 32 | Citations (PDF) |
| 275 | Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology | 27.4 | 57 | Citations (PDF) |
| 276 | Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas | 6.8 | 59 | Citations (PDF) |
| 277 | Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma | 2.3 | 8 | Citations (PDF) |
| 278 | Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | 5.5 | 68 | Citations (PDF) |
| 279 | Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma 2018, 6, | | 242 | Citations (PDF) |
| 280 | The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma | 4.2 | 111 | Citations (PDF) |
| 281 | Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors | 25.2 | 551 | Citations (PDF) |
| 282 | Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC) | 0.5 | 14 | Citations (PDF) |
| 283 | Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma | 33.0 | 1,153 | Citations (PDF) |
| 284 | Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era | 2.2 | 16 | Citations (PDF) |
| 285 | Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy | 0.9 | 37 | Citations (PDF) |
| 286 | Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA | 5.8 | 67 | Citations (PDF) |
| 287 | Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer | 4.0 | 78 | Citations (PDF) |
| 288 | Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status | 2.3 | 27 | Citations (PDF) |
| 289 | Radiogenomics in renal cell carcinoma | 1.7 | 41 | Citations (PDF) |
| 290 | Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling | 2.1 | 109 | Citations (PDF) |
| 291 | Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium | 2.1 | 75 | Citations (PDF) |
| 292 | Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer | 2.3 | 8 | Citations (PDF) |
| 293 | Strategies to design clinical studies to identify predictive biomarkers in cancer research | 9.5 | 100 | Citations (PDF) |
| 294 | Systemic Therapy for Metastatic Renal-Cell Carcinoma | 34.5 | 1,207 | Citations (PDF) |
| 295 | Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data | 2.4 | 75 | Citations (PDF) |
| 296 | Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model | 3.4 | 58 | Citations (PDF) |
| 297 | Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma | 2.3 | 14 | Citations (PDF) |
| 298 | Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma | 34.5 | 3,255 | Citations (PDF) |
| 299 | Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients | 4.2 | 442 | Citations (PDF) |
| 300 | Risk Assessment in Small Renal Masses | 2.0 | 7 | Citations (PDF) |
| 301 | Comprehensive Analysis of Survival Outcomes in Non–Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials | 2.3 | 45 | Citations (PDF) |
| 302 | Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025 | 2.1 | 227 | Citations (PDF) |
| 303 | Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder | 2.1 | 125 | Citations (PDF) |
| 304 | Characterizing the outcomes of metastatic papillary renal cell carcinoma | 2.6 | 42 | Citations (PDF) |
| 305 | Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma | 2.1 | 133 | Citations (PDF) |
| 306 | Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications | 4.2 | 39 | Citations (PDF) |
| 307 | Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma | 2.1 | 51 | Citations (PDF) |
| 308 | Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States | 9.9 | 56 | Citations (PDF) |
| 309 | A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations | 33.0 | 562 | Citations (PDF) |
| 310 | Genome-wide association study identifies multiple risk loci for renal cell carcinoma | 13.7 | 127 | Citations (PDF) |
| 311 | Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation | 4.2 | 32 | Citations (PDF) |
| 312 | Complications After Metastasectomy for Renal Cell Carcinoma—A Population-based Assessment | 2.1 | 56 | Citations (PDF) |
| 313 | National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer | 1.5 | 11 | Citations (PDF) |
| 314 | Prognostic Significance of Increases in Hemoglobin in Renal Cell Carcinoma Patients During Treatment With VEGF-directed Therapy | 2.3 | 13 | Citations (PDF) |
| 315 | Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non–Lymph Node Distant Metastasis | 2.3 | 4 | Citations (PDF) |
| 316 | Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology | 12.6 | 495 | Citations (PDF) |
| 317 | In Reply | 3.4 | 0 | Citations (PDF) |
| 318 | Recommendations for the Management of Rare Kidney Cancers | 2.1 | 40 | Citations (PDF) |
| 319 | The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE® Military Database | 4.2 | 13 | Citations (PDF) |
| 320 | Neoadjuvant chemotherapy prior to radical cystectomy for muscle‐invasive bladder cancer with variant histology | 4.0 | 170 | Citations (PDF) |
| 321 | Pan-urologic cancer genomic subtypes that transcend tissue of origin | 13.7 | 56 | Citations (PDF) |
| 322 | Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma | 2.1 | 47 | Citations (PDF) |
| 323 | ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis | 5.0 | 26 | Citations (PDF) |
| 324 | Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma | 2.3 | 40 | Citations (PDF) |
| 325 | Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category | 2.1 | 15 | Citations (PDF) |
| 326 | Effect of Metformin Use on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma | 2.3 | 27 | Citations (PDF) |
| 327 | Immunotherapy in the Elderly | 3.5 | 20 | Citations (PDF) |
| 328 | Exceptional Response to Palbociclib in Metastatic Collecting Duct Carcinoma Bearing a CDKN2A Homozygous Deletion | 1.9 | 17 | Citations (PDF) |
| 329 | Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series 2017, 5, | | 42 | Citations (PDF) |
| 330 | Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC) | 0.5 | 17 | Citations (PDF) |
| 331 | Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria | 1.3 | 17 | Citations (PDF) |
| 332 | Risk factors and model for predicting toxicity‐related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium | 4.0 | 33 | Citations (PDF) |
| 333 | Association between very small tumour size and increased cancer‐specific mortality after radical prostatectomy in lymph node‐positive prostate cancer | 3.2 | 15 | Citations (PDF) |
| 334 | Suicide and accidental deaths among patients with non‐metastatic prostate cancer | 3.2 | 42 | Citations (PDF) |
| 335 | Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma | 4.0 | 18 | Citations (PDF) |
| 336 | A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor‐targeted therapies | 4.0 | 19 | Citations (PDF) |
| 337 | Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma | 2.3 | 13 | Citations (PDF) |
| 338 | Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma | 3.5 | 12 | Citations (PDF) |
| 339 | Asian Americans and prostate cancer: A nationwide population-based analysis | 1.8 | 37 | Citations (PDF) |
| 340 | Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma | 2.3 | 1 | Citations (PDF) |
| 341 | Treatment of Advanced Renal-Cell Carcinoma | 34.5 | 26 | Citations (PDF) |
| 342 | Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma | 33.0 | 594 | Citations (PDF) |
| 343 | Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma 2016, 4, | | 12 | Citations (PDF) |
| 344 | Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma | 6.8 | 268 | Citations (PDF) |
| 345 | Determinants of cancer screening in Asian-Americans | 1.7 | 44 | Citations (PDF) |
| 346 | First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium | 4.9 | 62 | Citations (PDF) |
| 347 | Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups | 4.2 | 72 | Citations (PDF) |
| 348 | Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer | 1.1 | 13 | Citations (PDF) |
| 349 | National sociodemographic disparities in the treatment of high‐risk prostate cancer: Do academic cancer centers perform better than community cancer centers? | 4.0 | 34 | Citations (PDF) |
| 350 | Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures | 8.1 | 907 | Citations (PDF) |
| 351 | Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma | 3.4 | 53 | Citations (PDF) |
| 352 | Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma | 12.6 | 41 | Citations (PDF) |
| 353 | Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer | 12.6 | 12 | Citations (PDF) |
| 354 | Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial | 27.4 | 919 | Citations (PDF) |
| 355 | Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma | 6.3 | 343 | Citations (PDF) |
| 356 | Landscape of tumor-infiltrating T cell repertoire of human cancers | 25.2 | 326 | Citations (PDF) |
| 357 | The influence of marital status on the use of breast, cervical, and colorectal cancer screening | 2.8 | 112 | Citations (PDF) |
| 358 | Statins and survival outcomes in patients with metastatic renal cell carcinoma | 4.9 | 43 | Citations (PDF) |
| 359 | Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy | 4.2 | 47 | Citations (PDF) |
| 360 | Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy | 5.5 | 10 | Citations (PDF) |
| 361 | Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center | 2.3 | 11 | Citations (PDF) |
| 362 | Prevalence of Nonrecommended Screening for Prostate Cancer and Breast Cancer in the United States | 14.3 | 5 | Citations (PDF) |
| 363 | Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012 | 1.8 | 18 | Citations (PDF) |
| 364 | Radiologic Heterogeneity in Responses to Anti–PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma | 4.2 | 52 | Citations (PDF) |
| 365 | Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial | 2.1 | 337 | Citations (PDF) |
| 366 | Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response | 3.5 | 44 | Citations (PDF) |
| 367 | Determinants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary Era | 4.2 | 38 | Citations (PDF) |
| 368 | The impact of Medicare eligibility on cancer screening behaviors | 2.8 | 23 | Citations (PDF) |
| 369 | Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma | 6.8 | 224 | Citations (PDF) |
| 370 | Occult High-risk Disease in Clinically Low-risk Prostate Cancer with ≥50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk? | 1.4 | 20 | Citations (PDF) |
| 371 | Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma | 2.3 | 38 | Citations (PDF) |
| 372 | Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy | 2.1 | 143 | Citations (PDF) |
| 373 | Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial | 62.1 | 601 | Citations (PDF) |
| 374 | Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy | 14.3 | 112 | Citations (PDF) |
| 375 | Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling | 2.1 | 109 | Citations (PDF) |
| 376 | Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma | 2.1 | 63 | Citations (PDF) |
| 377 | Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma | 34.5 | 1,259 | Citations (PDF) |
| 378 | Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma | 4.2 | 60 | Citations (PDF) |
| 379 | Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9? | 3.2 | 48 | Citations (PDF) |
| 380 | Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer | 14.3 | 96 | Citations (PDF) |
| 381 | Risk of prostate cancer mortality in men with a history of prior cancer | 3.2 | 22 | Citations (PDF) |
| 382 | Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project | 9.9 | 29 | Citations (PDF) |
| 383 | HER2 as a target in invasive urothelial carcinoma | 2.6 | 60 | Citations (PDF) |
| 384 | Kidney Cancer, Version 3.2015 | 12.6 | 210 | Citations (PDF) |
| 385 | Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study | 12.6 | 44 | Citations (PDF) |
| 386 | The Right Drug for the Right Patient: Navigating Systemic Therapy Options in Metastatic Renal Cell Carcinoma and Future Directions | 12.6 | 2 | Citations (PDF) |
| 387 | Cost Implications and Complications of Overtreatment of Low-Risk Prostate Cancer in the United States | 12.6 | 83 | Citations (PDF) |
| 388 | Testicular Cancer, Version 2.2015 | 12.6 | 108 | Citations (PDF) |
| 389 | An evaluation of the ‘weekend effect’ in patients admitted with metastatic prostate cancer | 3.2 | 8 | Citations (PDF) |
| 390 | ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3) | 2.1 | 16 | Citations (PDF) |
| 391 | Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor‐risk metastatic renal cell carcinoma | 4.0 | 64 | Citations (PDF) |
| 392 | High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes | 2.3 | 37 | Citations (PDF) |
| 393 | Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study 2015, 3, | | 86 | Citations (PDF) |
| 394 | Who Bears the Greatest Burden of Aggressive Treatment of Indolent Prostate Cancer? | 2.0 | 21 | Citations (PDF) |
| 395 | Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer | 2.1 | 47 | Citations (PDF) |
| 396 | Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma | 4.2 | 251 | Citations (PDF) |
| 397 | Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials | 5.0 | 43 | Citations (PDF) |
| 398 | Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy for Urothelial Carcinoma | 2.3 | 2 | Citations (PDF) |
| 399 | Burden of Hospital Admissions and Utilization of Hospice Care in Metastatic Prostate Cancer Patients | 1.4 | 24 | Citations (PDF) |
| 400 | Incidence and determinants of 1-month mortality after cancer-directed surgery | 9.9 | 16 | Citations (PDF) |
| 401 | Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma | 9.9 | 268 | Citations (PDF) |
| 402 | Novel Roles of c-Met in the Survival of Renal Cancer Cells through the Regulation of HO-1 and PD-L1 Expression | 2.2 | 147 | Citations (PDF) |
| 403 | RNA-seq Reveals Aurora Kinase–Driven mTOR Pathway Activation in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma | 3.1 | 40 | Citations (PDF) |
| 404 | Outcome of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium | 2.3 | 91 | Citations (PDF) |
| 405 | Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials | 5.0 | 10 | Citations (PDF) |
| 406 | Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging | 1.8 | 16 | Citations (PDF) |
| 407 | IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma | 5.5 | 35 | Citations (PDF) |
| 408 | Association Between Older Age and Increasing Gleason Score | 2.3 | 28 | Citations (PDF) |
| 409 | Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway | 4.0 | 196 | Citations (PDF) |
| 410 | Cancer-Specific Mortality of Asian Americans Diagnosed With Cancer: A Nationwide Population-Based Assessment | 4.6 | 79 | Citations (PDF) |
| 411 | Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer | 4.2 | 121 | Citations (PDF) |
| 412 | Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors | 5.0 | 36 | Citations (PDF) |
| 413 | Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors | 5.0 | 123 | Citations (PDF) |
| 414 | The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study | 27.4 | 357 | Citations (PDF) |
| 415 | Angiotensin System Inhibitors and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma | 6.8 | 131 | Citations (PDF) |
| 416 | Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study | 27.4 | 319 | Citations (PDF) |
| 417 | Depth of Remission is a Prognostic Factor for Survival in Patients with Metastatic Renal Cell Carcinoma | 2.1 | 71 | Citations (PDF) |
| 418 | Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial | 6.8 | 231 | Citations (PDF) |
| 419 | Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma | 34.5 | 1,159 | Citations (PDF) |
| 420 | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma | 34.5 | 5,511 | Citations (PDF) |
| 421 | Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting | 1.8 | 14 | Citations (PDF) |
| 422 | Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design | 2.3 | 5 | Citations (PDF) |
| 423 | RECIST 1.1 Compared With RECIST 1.0 in Patients With Advanced Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor–Targeted Therapy | 4.1 | 24 | Citations (PDF) |
| 424 | Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States | 1.8 | 38 | Citations (PDF) |
| 425 | Contemporary nationwide patterns of self-reported prostate-specific antigen screening in US veterans | 1.8 | 9 | Citations (PDF) |
| 426 | Definition and Validation of “Favorable High-Risk Prostate Cancer”: Implications for Personalizing Treatment of Radiation-Managed Patients | 1.5 | 41 | Citations (PDF) |
| 427 | Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies | 2.1 | 43 | Citations (PDF) |
| 428 | Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma | 4.9 | 86 | Citations (PDF) |
| 429 | Diagnosis of Renal Cell Carcinoma | 1.4 | 7 | Citations (PDF) |
| 430 | Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database Consortium | 2.3 | 12 | Citations (PDF) |
| 431 | Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010 | 1.8 | 22 | Citations (PDF) |
| 432 | Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations | 16.5 | 110 | Citations (PDF) |
| 433 | Future Directions and Targeted Therapies in Bladder Cancer | 2.2 | 22 | Citations (PDF) |
| 434 | Association of androgen‐deprivation therapy with excess cardiac‐specific mortality in men with prostate cancer | 3.2 | 72 | Citations (PDF) |
| 435 | The burden of skeletal-related events in patients with prostate cancer and bone metastasis | 1.8 | 27 | Citations (PDF) |
| 436 | Income inequality and treatment of African American men with high-risk prostate cancer | 1.8 | 59 | Citations (PDF) |
| 437 | A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer | 2.1 | 126 | Citations (PDF) |
| 438 | Impact of the Number of Prior Lines of Therapy and Prior Perioperative Chemotherapy in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma: Implications for Trial Design | 2.3 | 10 | Citations (PDF) |
| 439 | Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors | 2.3 | 19 | Citations (PDF) |
| 440 | Identification of ALK Gene Alterations in Urothelial Carcinoma | 2.3 | 12 | Citations (PDF) |
| 441 | Qtc Interval Prolongation with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: a Systematic Review and Meta-Analysis | 9.9 | 0 | Citations (PDF) |
| 442 | Phase 2 Clinical Evaluation of Preclinically Defined Biomarkers for Vascular Endothelial Growth Factor (Vegf) Tyrosine Kinase Inhibitor (Tki) Tivozanib in Renal Cell Carcinoma (Rcc) | 9.9 | 1 | Citations (PDF) |
| 443 | Somatic
ERCC2
Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma | 25.1 | 601 | Citations (PDF) |
| 444 | Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma | 6.8 | 80 | Citations (PDF) |
| 445 | Genomic investigation of etiologic heterogeneity: methodologic challenges | 2.5 | 12 | Citations (PDF) |
| 446 | First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC | 5.5 | 68 | Citations (PDF) |
| 447 | Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients | 5.5 | 18 | Citations (PDF) |
| 448 | The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act | 4.0 | 68 | Citations (PDF) |
| 449 | Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials | 9.9 | 143 | Citations (PDF) |
| 450 | Disparities in selective referral for cancer surgeries: implications for the current healthcare delivery system | 1.9 | 43 | Citations (PDF) |
| 451 | A phase I study of cabozantinib (XL184) in patients with renal cell cancer | 9.9 | 151 | Citations (PDF) |
| 452 | FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder | 2.6 | 86 | Citations (PDF) |
| 453 | Lack of reduction in racial disparities in cancer‐specific mortality over a 20‐year period | 4.0 | 232 | Citations (PDF) |
| 454 | A phase 2, single‐arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy | 4.0 | 31 | Citations (PDF) |
| 455 | Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: Implications for alternative response criteria | 4.0 | 45 | Citations (PDF) |
| 456 | PD-L1 expression in nonclear-cell renal cell carcinoma | 9.9 | 277 | Citations (PDF) |
| 457 | PD-1 Blockade in Renal Cell Carcinoma: To Equilibrium and Beyond | 4.2 | 48 | Citations (PDF) |
| 458 | A nomogram including baseline prognostic factors to estimate the activity of second‐line therapy for advanced urothelial carcinoma | 3.2 | 34 | Citations (PDF) |
| 459 | Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib | 34.5 | 262 | Citations (PDF) |
| 460 | MET as a Target in Papillary Renal Cell Carcinoma | 6.8 | 21 | Citations (PDF) |
| 461 | 10% Tumor Diameter Shrinkage on the First Follow-Up Computed Tomography Predicts Clinical Outcome in Patients With Advanced Renal Cell Carcinoma Treated With Angiogenesis Inhibitors: A Follow-Up Validation Study | 3.4 | 49 | Citations (PDF) |
| 462 | Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized Trials | 2.1 | 388 | Citations (PDF) |
| 463 | Refusal of Curative Radiation Therapy and Surgery Among Patients With Cancer | 1.5 | 80 | Citations (PDF) |
| 464 | Efficacy of Targeted Therapy for Metastatic Renal Cell Carcinoma in the Elderly Patient Population | 2.3 | 28 | Citations (PDF) |
| 465 | Sequential Targeted Therapy After Pazopanib Therapy in Patients With Metastatic Renal Cell Cancer: Efficacy and Toxicity | 2.3 | 11 | Citations (PDF) |
| 466 | Metabolic complications with the use of mTOR inhibitors for cancer therapy | 9.5 | 77 | Citations (PDF) |
| 467 | Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer | 2.1 | 33 | Citations (PDF) |
| 468 | Prognostic Significance of Bone Metastases and Bisphosphonate Therapy in Patients with Renal Cell Carcinoma | 2.1 | 79 | Citations (PDF) |
| 469 | Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy | 2.1 | 242 | Citations (PDF) |
| 470 | ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma | 2.1 | 262 | Citations (PDF) |
| 471 | Precision medicine for metastatic renal cell carcinoma | 1.8 | 16 | Citations (PDF) |
| 472 | Cytoreductive nephrectomy in patients with metastatic non‐clear‐cell renal cell carcinoma (
RCC
) | 3.2 | 64 | Citations (PDF) |
| 473 | Recognizing and Managing Left Ventricular Dysfunction Associated With Therapeutic Inhibition of the Vascular Endothelial Growth Factor Signaling Pathway | 0.5 | 37 | Citations (PDF) |
| 474 | Mental health outcomes in elderly men with prostate cancer | 1.8 | 66 | Citations (PDF) |
| 475 | Trends in Disparate Treatment of African American Men With Localized Prostate Cancer Across National Comprehensive Cancer Network Risk Groups | 1.4 | 93 | Citations (PDF) |
| 476 | The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma | 33.0 | 798 | Citations (PDF) |
| 477 | Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium | 2.1 | 422 | Citations (PDF) |
| 478 | Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib | 25.1 | 277 | Citations (PDF) |
| 479 | First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium | 2.3 | 10 | Citations (PDF) |
| 480 | Racial Disparities in Prostate Cancer–Specific Mortality in Men With Low-Risk Prostate Cancer | 2.3 | 49 | Citations (PDF) |
| 481 | Weight Gain on Androgen Deprivation Therapy: Which Patients Are at Highest Risk? | 1.4 | 18 | Citations (PDF) |
| 482 | A Systematic Review and Meta-analysis of Adjuvant and Neoadjuvant Chemotherapy for Upper Tract Urothelial Carcinoma | 2.1 | 220 | Citations (PDF) |
| 483 | The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium | 2.1 | 76 | Citations (PDF) |
| 484 | A Population-Based Overview of Sequences of Targeted Therapy in Metastatic Renal Cell Carcinoma | 2.3 | 25 | Citations (PDF) |
| 485 | Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma | 2.3 | 29 | Citations (PDF) |
| 486 | Adrenocortical carcinoma: The management of metastatic disease | 5.0 | 53 | Citations (PDF) |
| 487 | Racial disparities in an aging population: The relationship between age and race in the management of African American men with high-risk prostate cancer | 1.8 | 23 | Citations (PDF) |
| 488 | Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer | 1.8 | 86 | Citations (PDF) |
| 489 | Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy | 2.1 | 80 | Citations (PDF) |
| 490 | Analgesic use and the risk of kidney cancer: A meta‐analysis of epidemiologic studies | 4.3 | 90 | Citations (PDF) |
| 491 | Kidney Cancer, Version 2.2014 | 12.6 | 57 | Citations (PDF) |
| 492 | NCCN Working Group Report: Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies | 12.6 | 19 | Citations (PDF) |
| 493 | QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors | 5.5 | 134 | Citations (PDF) |
| 494 | Expression of Ror2 Mediates Invasive Phenotypes in Renal Cell Carcinoma | 2.3 | 23 | Citations (PDF) |
| 495 | Use of Surveillance Imaging Following Treatment of Small Renal Masses | 4.2 | 18 | Citations (PDF) |
| 496 | The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients | 3.2 | 50 | Citations (PDF) |
| 497 | Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma | 34.5 | 1,824 | Citations (PDF) |
| 498 | Comparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007 | 3.2 | 34 | Citations (PDF) |
| 499 | Marital Status and Survival in Patients With Cancer | 16.9 | 933 | Citations (PDF) |
| 500 | Optimizing Bone Health and Minimizing Skeletal Morbidity in Men with Prostate Cancer | 2.2 | 6 | Citations (PDF) |
| 501 | Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria | 4.0 | 219 | Citations (PDF) |
| 502 | Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer | 4.0 | 2 | Citations (PDF) |
| 503 | Prognostic Factors of Survival for Patients With Metastatic Renal Cell Carcinoma With Brain Metastases Treated With Targeted Therapy: Results From the International Metastatic Renal Cell Carcinoma Database Consortium | 2.3 | 69 | Citations (PDF) |
| 504 | External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study | 27.4 | 974 | Citations (PDF) |
| 505 | Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma | 16.9 | 442 | Citations (PDF) |
| 506 | Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study | 27.4 | 52 | Citations (PDF) |
| 507 | Impact of Response to Prior Chemotherapy in Patients With Advanced Urothelial Carcinoma Receiving Second-Line Therapy: Implications for Trial Design | 2.3 | 21 | Citations (PDF) |
| 508 | Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET) | 1.8 | 44 | Citations (PDF) |
| 509 | Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials | 5.0 | 69 | Citations (PDF) |
| 510 | Reduced Penile Size and Treatment Regret in Men With Recurrent Prostate Cancer After Surgery, Radiotherapy Plus Androgen Deprivation, or Radiotherapy Alone | 1.4 | 32 | Citations (PDF) |
| 511 | Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials | 2.1 | 112 | Citations (PDF) |
| 512 | Cardiovascular complications associated with novel angiogenesis inhibitors: Emerging evidence and evolving perspectives | 7.2 | 113 | Citations (PDF) |
| 513 | Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer | 1.1 | 5 | Citations (PDF) |
| 514 | Reply | 1.4 | 0 | Citations (PDF) |
| 515 | Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy | 9.9 | 165 | Citations (PDF) |
| 516 | Rationale for and Review of Neoadjuvant Therapy Prior to Radical Prostatectomy for Patients with High-Risk Prostate CancerDrugs, 2013, 73, 1417-1430 | 11.4 | 41 | Citations (PDF) |
| 517 | The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine | 5.5 | 14 | Citations (PDF) |
| 518 | Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms | 9.9 | 34 | Citations (PDF) |
| 519 | Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients | 1.8 | 41 | Citations (PDF) |
| 520 | The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma | 6.8 | 85 | Citations (PDF) |
| 521 | Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors | 9.9 | 32 | Citations (PDF) |
| 522 | Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors | 5.5 | 34 | Citations (PDF) |
| 523 | Clinical Treatment Decisions for Advanced Renal Cell Cancer | 12.6 | 18 | Citations (PDF) |
| 524 | Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis | 3.2 | 31 | Citations (PDF) |
| 525 | A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma | 2.5 | 389 | Citations (PDF) |
| 526 | Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy | 9.9 | 123 | Citations (PDF) |
| 527 | Arterial Thromboembolism in Cancer Patients Treated With Cisplatin: A Systematic Review and Meta-analysis | 4.6 | 41 | Citations (PDF) |
| 528 | Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer | 16.9 | 171 | Citations (PDF) |
| 529 | Severe Pazopanib-Induced Hepatotoxicity: Clinical and Histologic Course in Two Patients | 16.9 | 44 | Citations (PDF) |
| 530 | Testicular Cancer | 12.6 | 76 | Citations (PDF) |
| 531 | BRAF Mutations in Metanephric Adenoma of the Kidney | 2.1 | 114 | Citations (PDF) |
| 532 | Influence of Androgen Deprivation Therapy on All-Cause Mortality in Men With High-Risk Prostate Cancer and a History of Congestive Heart Failure or Myocardial Infarction | 1.5 | 71 | Citations (PDF) |
| 533 | Posttreatment Prostate Specific Antigen Nadir Predicts Prostate Cancer Specific and All Cause Mortality | 4.2 | 23 | Citations (PDF) |
| 534 | Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: Results from a medical chart review study | 1.8 | 18 | Citations (PDF) |
| 535 | RET protein expression in papillary renal cell carcinoma | 1.8 | 16 | Citations (PDF) |
| 536 | Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy | 2.0 | 21 | Citations (PDF) |
| 537 | Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma | 5.5 | 31 | Citations (PDF) |
| 538 | Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine | 4.9 | 17 | Citations (PDF) |
| 539 | Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings and correlation with clinical outcome | 4.9 | 95 | Citations (PDF) |
| 540 | Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study | 27.4 | 117 | Citations (PDF) |
| 541 | ABO blood group and risk of renal cell cancer | 2.0 | 38 | Citations (PDF) |
| 542 | Factors Associated with the Adoption of Minimally Invasive Radical Prostatectomy in the United States | 4.2 | 20 | Citations (PDF) |
| 543 | External Validation of the Association of Progression-Free Survival at 6 Months (PFS6) with Overall Survival at 12 Months (OS12) in Second-Line Therapy for Advanced Urothelial Carcinoma (UC) | 9.9 | 2 | Citations (PDF) |
| 544 | Clinical Activity and Safety of Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Previously Treated, Metastatic Renal Cell Carcinoma (MRCC) | 9.9 | 6 | Citations (PDF) |
| 545 | Prognostic Stratification of Advanced Urothelial Carcinoma (UC) Receiving Second-Line Systemic Therapy Including Time from Prior Chemotherapy (TFPC) as a Prognostic Factor | 9.9 | 0 | Citations (PDF) |
| 546 | Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high‐risk localized prostate cancer | 4.0 | 48 | Citations (PDF) |
| 547 | The Double Edged Sword of Bleeding and Clotting from VEGF Inhibition in Renal Cancer Patients | 4.2 | 41 | Citations (PDF) |
| 548 | Sequencing of Agents for Metastatic Renal Cell Carcinoma: Can We Customize Therapy? | 2.1 | 55 | Citations (PDF) |
| 549 | Comparative Analysis of Outcomes and Costs Following Open Radical Cystectomy Versus Robot-Assisted Laparoscopic Radical Cystectomy: Results From the US Nationwide Inpatient Sample | 2.1 | 160 | Citations (PDF) |
| 550 | The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor‐targeted therapy | 4.0 | 25 | Citations (PDF) |
| 551 | Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts | 4.0 | 29 | Citations (PDF) |
| 552 | The Evolving Landscape of Metastatic Renal Cell Carcinoma | 4.4 | 10 | Citations (PDF) |
| 553 | Sequential Targeted Therapy Following Pazopanib (PZ) in Patients (PTS) with Metastatic Renal Cell Cancer (MRCC): Efficacy and Toxicity | 9.9 | 0 | Citations (PDF) |
| 554 | Metastasectomy After Targeted Therapy in Patients With Advanced Renal Cell Carcinoma | 4.2 | 116 | Citations (PDF) |
| 555 | Systemic Therapy for Metastatic Non–Clear-Cell Renal Cell Carcinoma: Recent Progress and Future Directions | 2.2 | 28 | Citations (PDF) |
| 556 | The Impact of Cytoreductive Nephrectomy on Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Targeted Therapy | 4.2 | 332 | Citations (PDF) |
| 557 | Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid | 2.6 | 41 | Citations (PDF) |
| 558 | Recommendations for Post-Prostatectomy Radiation Therapy in the United States Before and After the Presentation of Randomized Trials | 4.2 | 78 | Citations (PDF) |
| 559 | Haematologic toxicities associated with the addition of bevacizumab in cancer patients | 4.9 | 45 | Citations (PDF) |
| 560 | Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure | 4.9 | 36 | Citations (PDF) |
| 561 | Determinants of Performing Radical Prostatectomy Pelvic Lymph Node Dissection and the Number of Lymph Nodes Removed in Elderly Men | 1.4 | 34 | Citations (PDF) |
| 562 | Thermal Ablation vs Surgery for Localized Kidney Cancer: a Surveillance, Epidemiology, and End Results (SEER) Database Analysis | 1.4 | 101 | Citations (PDF) |
| 563 | Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma | 1.8 | 10 | Citations (PDF) |
| 564 | Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis | 3.2 | 51 | Citations (PDF) |
| 565 | Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: A meta-analysis of clinical trials | 5.0 | 58 | Citations (PDF) |
| 566 | Comparison of Four Early Posttherapy Imaging Changes (EPTIC; RECIST 1.0, Tumor Shrinkage, Computed Tomography Tumor Density, Choi Criteria) in Assessing Outcome to Vascular Endothelial Growth Factor–Targeted Therapy in Patients With Advanced Renal Cell Carcinoma | 2.1 | 104 | Citations (PDF) |
| 567 | ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease | 2.1 | 129 | Citations (PDF) |
| 568 | Impact of prostate‐specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen‐deprivation therapy | 2.1 | 61 | Citations (PDF) |
| 569 | Progression‐free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy | 4.0 | 75 | Citations (PDF) |
| 570 | Utilization and expense of adjuvant cancer therapies following radical prostatectomy | 4.0 | 30 | Citations (PDF) |
| 571 | Risk of All-Cause and Prostate Cancer–Specific Mortality After Brachytherapy in Men With Small Prostate Size | 1.5 | 11 | Citations (PDF) |
| 572 | Pazopanib: Clinical development of a potent anti-angiogenic drug | 5.0 | 171 | Citations (PDF) |
| 573 | Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes | 9.9 | 140 | Citations (PDF) |
| 574 | Everolimus- and Temsirolimus-Associated Enteritis: Report of Three Cases | 16.9 | 12 | Citations (PDF) |
| 575 | Association of Androgen Deprivation Therapy With Cardiovascular Death in Patients With Prostate Cancer | 16.5 | 408 | Citations (PDF) |
| 576 | Prospective Evaluation of Analgesic Use and Risk of Renal Cell Cancer | 8.1 | 69 | Citations (PDF) |
| 577 | Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group | 6.8 | 176 | Citations (PDF) |
| 578 | Comorbidity, body mass index, and age and the risk of nonprostate‐cancer‐specific mortality after a postradiation prostate‐specific antigen recurrence | 4.0 | 11 | Citations (PDF) |
| 579 | Impact of postoperative prostate‐specific antigen disease recurrence and the use of salvage therapy on the risk of death | 4.0 | 38 | Citations (PDF) |
| 580 | Vascular endothelial growth factor‐targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma | 4.0 | 143 | Citations (PDF) |
| 581 | Sunitinib rechallenge in metastatic renal cell carcinoma patients | 4.0 | 127 | Citations (PDF) |
| 582 | Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice‐based on medical chart review | 3.2 | 68 | Citations (PDF) |
| 583 | Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear‐cell renal cell carcinoma receiving vascular endothelial growth factor‐targeted therapy | 3.2 | 83 | Citations (PDF) |
| 584 | Androgen‐suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke | 3.2 | 22 | Citations (PDF) |
| 585 | 11
C‐METHIONINE POSITRON‐EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY (PET‐CT) IN EVALUATING METASTATIC TRANSITIONAL CELL CARCINOMA RESPONSE TO SUNITINIB THERAPY | 3.2 | 1 | Citations (PDF) |
| 586 | Sunitinib-Induced Pseudoprogression After Whole-Brain Radiotherapy for Metastatic Renal Cell Carcinoma | 16.9 | 14 | Citations (PDF) |
| 587 | Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving Vascular Endothelial Growth Factor–Signaling Inhibitors | 6.6 | 113 | Citations (PDF) |
| 588 | Review: Updates on novel therapies for metastatic renal cell carcinoma | 3.6 | 23 | Citations (PDF) |
| 589 | Elicitation of health state utilities in metastatic renal cell carcinoma | 2.1 | 58 | Citations (PDF) |
| 590 | Reply | 1.4 | 1 | Citations (PDF) |
| 591 | Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy | 1.4 | 76 | Citations (PDF) |
| 592 | Which Patients With Undetectable PSA Levels 5 Years After Radical Prostatectomy Are Still at Risk of Recurrence?—Implications for a Risk-adapted Follow-up Strategy | 1.4 | 28 | Citations (PDF) |
| 593 | Risk of bleeding not increased by sorafenib or sunitinib – Authors' reply | 27.4 | 2 | Citations (PDF) |
| 594 | Time to prostate‐specific antigen nadir independently predicts overall survival in patients who have metastatic hormone‐sensitive prostate cancer treated with androgen‐deprivation therapy | 4.0 | 128 | Citations (PDF) |
| 595 | Optimizing recent advances in metastatic renal cell carcinoma | 4.2 | 9 | Citations (PDF) |
| 596 | A Case of Adult Metastatic Xp11 Translocation Renal Cell Carcinoma Treated Successfully With Sunitinib | 2.3 | 26 | Citations (PDF) |
| 597 | Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis* | 2.1 | 28 | Citations (PDF) |
| 598 | Sunitinib in renal-cell carcinoma: expanded indications | 27.4 | 5 | Citations (PDF) |
| 599 | Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials | 27.4 | 281 | Citations (PDF) |
| 600 | Recent advances in the systemic treatment of metastatic papillary renal cancer | 2.5 | 29 | Citations (PDF) |
| 601 | Response of Renal Cell Carcinoma Pancreatic Metastasis to Sunitinib Treatment: A Retrospective Analysis | 4.2 | 27 | Citations (PDF) |
| 602 | Sunitinib‐induced macrocytosis in patients with metastatic renal cell carcinoma | 4.0 | 46 | Citations (PDF) |
| 603 | An association between renal cell carcinoma and multiple myeloma: a case series and clinical implications | 3.2 | 29 | Citations (PDF) |
| 604 | Factors Associated with Outcome in Patients with Advanced Renal Cell Carcinoma in the Era of Antiangiogenic Agents | 2.3 | 7 | Citations (PDF) |
| 605 | Recent Developments in Research on Kidney Cancer: Highlights from Urological and Oncological Congresses in 2007 | 0.1 | 3 | Citations (PDF) |
| 606 | von Hippel-Lindau Gene Status and Response to Vascular Endothelial Growth Factor Targeted Therapy for Metastatic Clear Cell Renal Cell Carcinoma | 4.2 | 187 | Citations (PDF) |
| 607 | Patterns of Care for Radical Prostatectomy in the United States From 2003 to 2005 | 4.2 | 44 | Citations (PDF) |
| 608 | A Model That Predicts the Probability of Positive Imaging in Prostate Cancer Cases With Biochemical Failure After Initial Definitive Local Therapy | 4.2 | 105 | Citations (PDF) |
| 609 | Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties | 6.6 | 45 | Citations (PDF) |
| 610 | Predicting Outcome To Vegf-Targeted Therapy In Metastatic Clear-Cell Renal Cell Carcinoma: Data From Recent Studies | 2.3 | 20 | Citations (PDF) |
| 611 | The role of cytoreductive nephrectomy for renal cell carcinoma in the era of targeted therapy | 6.6 | 4 | Citations (PDF) |
| 612 | In Reply | 16.9 | 0 | Citations (PDF) |
| 613 | Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma | 16.9 | 381 | Citations (PDF) |
| 614 | Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma | 9.9 | 58 | Citations (PDF) |
| 615 | Prognostic Factors of Metastatic Renal Cell Carcinoma After Failure of Immunotherapy: New Paradigm From a Large Phase III Trial With Shark Cartilage Extract AE 941 | 4.2 | 60 | Citations (PDF) |
| 616 | Management of Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer | 2.0 | 28 | Citations (PDF) |
| 617 | Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy | 4.0 | 220 | Citations (PDF) |
| 618 | Differential expression of caveolin-1 in renal neoplasms | 4.0 | 23 | Citations (PDF) |
| 619 | The Expression of the Cytoskeletal Focal Adhesion Protein Paxillin in Breast Cancer Correlates with HER2 Overexpression and May Help Predict Response to Chemotherapy: A Retrospective Immunohistochemical Study | 4.0 | 37 | Citations (PDF) |
| 620 | Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR | 3.5 | 237 | Citations (PDF) |
| 621 | Phenoxodiol: Isoflavone analog with antineoplastic activity | 4.2 | 30 | Citations (PDF) |
| 622 | Endothelin receptor antagonists: Rationale, clinical development, and role in prostate cancer therapeutics | 4.2 | 20 | Citations (PDF) |
| 623 | The Current Role of Angiogenesis Inhibitors in the Treatment of Renal Cell Carcinoma | 1.9 | 35 | Citations (PDF) |
| 624 | Phase II study of lenalidomide in patients with metastatic renal cell carcinoma | 4.0 | 58 | Citations (PDF) |
| 625 | Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer | 9.9 | 40 | Citations (PDF) |
| 626 | Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy | 9.9 | 134 | Citations (PDF) |
| 627 | Daptomycin-Resistant Enterococcus faecium in a Patient With Acute Myeloid Leukemia | 3.7 | 69 | Citations (PDF) |
| 628 | Role of aromatase inhibitors in the treatment of breast cancer | 2.7 | 38 | Citations (PDF) |
| 629 | Acquired Activated Protein C Resistance in Myeloma Patients with Venous Thromboembolic Events | 2.7 | 11 | Citations (PDF) |
| 630 | An overview of targeted treatments in cancer | 2.7 | 91 | Citations (PDF) |
| 631 | Evolving role of pegylated interferons in metastatic renal cell carcinoma | 2.5 | 20 | Citations (PDF) |
| 632 | Hereditary hemorrhagic telangiectasia, idiopathic thrombocytopenic purpura, and chronic lymphocytic leukemia treated with rituximab | 2.0 | 4 | Citations (PDF) |
| 633 | Why shouldn't we use warfarin alone to treat acute venous thrombosis? | 1.3 | 5 | Citations (PDF) |
| 634 | Evaluation of statin use and renal cell carcinoma risk identifies sex-specific associations with RCC subtypes | 1.8 | 1 | Citations (PDF) |
| 635 | State-of-the-Art Imaging in Antibody-Drug Conjugate Treatment for Advanced Bladder Cancer | 2.2 | 1 | Citations (PDF) |
| 636 | Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer | 4.6 | 0 | Citations (PDF) |
| 637 | Indeterminate Surgical Margins (Rx) in Renal Cell Carcinoma Surgery: Rates, Predictive Factors, and Impact on Overall Survival | 2.3 | 1 | Citations (PDF) |
| 638 | Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC) | 2.3 | 1 | Citations (PDF) |
| 639 | Immunotherapy rechallenge in metastatic renal cell carcinoma: a meta-analysis of randomized clinical trials | 3.4 | 2 | Citations (PDF) |
| 640 | Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers | 251.5 | 1 | Citations (PDF) |
| 641 | New Medicare Payment Policy on Drug Shortages | 3.7 | 0 | Citations (PDF) |
| 642 | Use of genomic dedifferentiation signature to predict clinical outcomes with doublet vs triplet therapy in the phase III COSMIC-313 trial. | 16.9 | 0 | Citations (PDF) |
| 643 | Single-cell transcriptomic investigation of the cell-of-origin and oncogenic pathways across variant histologies of renal cell carcinoma. | 16.9 | 0 | Citations (PDF) |
| 644 | Abstract PR006: Evidence for the involvement of HIF-2α biology in the clinical efficacy of casdatifan, a novel HIF-2α inhibitor, in clear cell renal cell carcinoma (ccRCC) | 3.8 | 0 | Citations (PDF) |
| 645 | Abstract PR014: Shared germline architecture across renal cell carcinoma, coronary artery disease, and clonal hematopoiesis implicates a regulatory haplotype at the
TERT
promoter | 3.8 | 0 | Citations (PDF) |
| 646 | Cardiac biomarkers in patients with renal cell carcinoma treated with immune checkpoint inhibitors | 3.4 | 0 | Citations (PDF) |
| 647 | Abstract 2762: LLM-based extraction of immunotherapy toxicities reveals severity-dependent effects on overall survival. | 3.8 | 0 | Citations (PDF) |
| 648 | Abstract 7898: Clinical benefit of the HIF-2α inhibitor casdatifan (Cas) across molecular subtypes in clear cell renal cell carcinoma (ccRCC) patients from the ARC-20 Clinical Study | 3.8 | 0 | Citations (PDF) |
| 649 | Radiopharmaceutical Therapy in Oncology: Perspectives from Transatlantic Experts | 2.6 | 2 | Citations (PDF) |
| 650 | From Anatomy to Theranostics: Toni Choueiri Talks with Ken Herrmann About the Evolution of Genitourinary Oncology | 5.1 | 0 | Citations (PDF) |
| 651 | The clinical landscape of HIF2α inhibitors in oncology | 70.7 | 0 | Citations (PDF) |
| 652 | Current evidence and future directions for KIM-1 as a blood-based biomarker in RCC | 70.7 | 0 | Citations (PDF) |
| 653 | The seventh kidney cancer research summit: progress in accelerating cures | 3.4 | 0 | Citations (PDF) |
| 654 | LITESPARK-033: Phase 3 study of belzutifan plus zanzalintinib versus cabozantinib for recurrent clear cell renal cell carcinoma during or after adjuvant anti–PD-(L)1 therapy. | 16.9 | 0 | Citations (PDF) |
| 655 | PEAK-1: A randomized, double-blind, active-control, multicenter phase 3 trial of casdatifan and cabozantinib versus placebo and cabozantinib in patients with advanced clear cell renal cell carcinoma. | 16.9 | 0 | Citations (PDF) |
